VCYT News and Press, Veracyte Inc. From 01/18/24

2024-01-18 21:08:20 ET Summary ARK Invest's 13F portfolio value increased by 29% this quarter, reaching approximately $16.89 billion. The top three holdings in the portfolio are Coinbase Global, UiPath, and Tesla. ARK Invest made new stakes in ProShares Bitcoin Strategy ETF an...

2024-01-08 14:03:23 ET More on Veracyte Veracyte's Strategic Growth Amid Volatility And Evolution In Genomic Diagnostics Veracyte, Inc. (VCYT) Q3 2023 Earnings Call Transcript Seeking Alpha’s Quant Rating on Veracyte Historical earnings data for Veracy...

Grew full-year revenue to between $358 million and $359 million, an increase of 21% Acquisition broadens Veracyte’s presence across the cancer care continuum Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced preliminary unaudite...

2023-12-29 00:25:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

Veracyte, Inc . (Nasdaq: VCYT) announced today that Marc Stapley, chief executive officer, and Rebecca Chambers, chief financial officer, will present at the 42 nd annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024, at 1:30 p.m. Pacific Time. A live audio webcast of the...

Veracyte, Inc. (Nasdaq: VCYT) announced that new data presented today at the 24th Annual Meeting of the Society of Urologic Oncology (SUO 2023) highlight clinical observations and translational research conducted by users of the company’s Decipher Prostate Genomic Classifier. These indep...

Non-invasive genomic test is designed to help physicians guide next steps for current and former smokers with lung nodules Veracyte, Inc. (Nasdaq: VCYT) announced that clinical validation data published in the journal CHEST show that the company’s Percepta Nasal Swab ...

Veracyte, Inc. (Nasdaq: VCYT) today announced that seven posters will be presented at the 24th Annual Meeting of the Society of Urologic Oncology (SUO 2023), where they will demonstrate the clinical performance of Veracyte’s Decipher Prostate Genomic Classifier in identifying patient...

2023-11-22 04:46:13 ET Summary Veracyte's Q3 2023 performance shows a robust 19% YOY revenue growth, driven by an increase in testing revenue and test volume. Financial health is strong with a high current ratio, positive operational cash flow, and low likelihood of needing additi...

2023-11-07 20:57:10 ET Veracyte, Inc. (VCYT) Q3 2023 Earnings Conference Call November 07, 2023 4:30 PM ET Company Participants Tristan Ribar – Vice President-Finance Marc Stapley – Chief Executive Officer Rebecca Chambers – Chief Financial O...